Abstract: Pharmaceutical compositions are described, the compositions consisting essentially of aqueous emulsions of a therapeutically effective quantity of a diarylheptanoid compound (such as curcumin). Methods for fabricating the compositions and using them are also described.

Abstract: Pharmaceutical compositions for treating, mitigating or preventing inflammatory skin diseases, disorders and/or pathologies are described, the compositions comprising a tetracycline-class antibiotic(s), omega fatty acid(s), and/or nicotinic acid or derivatives thereof. Methods for fabricating the compositions and using them are also described.

Abstract: Pharmaceutical compositions for treating, mitigating or preventing fungal nail diseases, disorders or pathologies are described, the compositions comprising at least one functionalized allylamine compound, at least one functionalized triazole compound, and at least one functionalized imidazole compound. Methods for fabricating the compositions and using them are also described.

Abstract: Pharmaceutical compositions for treating, mitigating or preventing kidney stone disease, bladder stone disease or ureter stone disease are described, the compositions comprising a reducing agent capable of undergoing thiol-disulfide exchange with cystine to form a mixed disulfide and a citrate of an alkali metal or alkaline earth metal. Methods for fabricating the compositions and using them are also described.

Abstract: Pharmaceutical compositions for treating, mitigating or preventing inflammatory skin diseases, disorders and/or pathologies are described, the compositions comprising a tetracycline-class antibiotic(s), omega fatty acid(s), and/or nicotinic acid or derivatives thereof. Methods for fabricating the compositions and using them are also described.

Abstract: Pharmaceutical compositions are described, the compositions comprising a therapeutically effective quantity of an active component and a quantity of a sterile gel. Methods for fabricating the compositions and using them for ophthalmic applications are also described.

Abstract: Pharmaceutical compositions and methods are described, the compositions comprising a benzodiazepine-based compound, a NMDA antagonist, a ?-blocker and antiemetic. Methods for fabricating the compositions and using them for anesthesiological applications are also described.

Abstract: Pharmaceutical compositions and methods for treating various male sexual dysfunction disorders, such as erectile dysfunction or Peyronie's disease, are described, the compositions comprising a combination of certain pharmaceutically active components (e.g., alprostadil, papaverine, phentolamine and pentoxifylline) and a pharmaceutically acceptable carrier. Methods for fabricating the compositions and using them are also described.

Abstract: Pharmaceutical ophthalmic compositions are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone), a combination of at least two solubilizing and suspending agents (of which one is a non-ionic polyoxyethlene-polyoxypropylene block copolymer), and a carrier. Methods for fabricating the compositions and using them are also described.

Abstract: Pharmaceutical ophthalmic compositions are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as prednisolone), a combination of at least two solubilizing and suspending agents (of which one is a non-ionic polyoxyethlene-polyoxypropylene block copolymer), and a carrier. Methods for fabricating the compositions and using them are also described.